Day One Biopharmaceuticals (DAWN) Set to Announce Earnings on Wednesday

Day One Biopharmaceuticals (NASDAQ:DAWN) is set to post its quarterly earnings results after the market closes on Wednesday, October 30th. Analysts expect Day One Biopharmaceuticals to post earnings of ($0.22) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.70. The company had revenue of $8.19 million for the quarter, compared to the consensus estimate of $0.90 million. On average, analysts expect Day One Biopharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Day One Biopharmaceuticals Stock Up 0.9 %

Shares of DAWN stock opened at $14.60 on Monday. The company has a 50 day moving average price of $14.14 and a 200-day moving average price of $14.38. Day One Biopharmaceuticals has a 52 week low of $9.76 and a 52 week high of $18.07. The firm has a market capitalization of $1.28 billion, a PE ratio of -5.82 and a beta of -1.51.

Analyst Ratings Changes

A number of brokerages have weighed in on DAWN. Needham & Company LLC boosted their target price on shares of Day One Biopharmaceuticals from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. Bank of America upgraded Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and upped their price objective for the company from $11.00 to $24.00 in a research report on Thursday, August 1st. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, August 1st. Piper Sandler reaffirmed an “overweight” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $35.71.

Insider Activity

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,232 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $31,248.00. Following the completion of the sale, the insider now owns 1,127,535 shares in the company, valued at approximately $15,785,490. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, General Counsel Adam Dubow sold 3,202 shares of the business’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $44,828.00. Following the transaction, the general counsel now owns 26,928 shares of the company’s stock, valued at approximately $376,992. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Samuel C. Blackman sold 2,232 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $31,248.00. Following the transaction, the insider now directly owns 1,127,535 shares of the company’s stock, valued at $15,785,490. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 48,748 shares of company stock worth $689,072 in the last three months. Company insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.